<DOC>
	<DOCNO>NCT02754219</DOCNO>
	<brief_summary>The objective study compare pharmacokinetics profile safety Evogliptin patient wit hepatic dysfunction versus healthy volunteer single oral dose Evogliptin</brief_summary>
	<brief_title>Pharmacokinetics Safety Evogliptin Subjects With Hepatic Dysfunction</brief_title>
	<detailed_description>When future evogliptin administer liver dysfunction patient , investgate whether dose adjustment necessary .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>&lt; Hepatic Dysfunction &gt; At least 6 month chronic liver disease ( Regardless cause hepatic dysfunction ) ChildPugh A B &lt; Healthy Control &gt; Subject follow condition : age ± 5 year , BMI ± 20 % , sex match hepatic dysfunction subject &lt; Hepatic Dysfunction &gt; ChildPugh C History Liver transplant &lt; Healthy Control &gt; History chronic liver disorder Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetes Mellitus , Type II</keyword>
</DOC>